Literature DB >> 12962840

Upper aerodigestive tract and lung tumors after liver transplantation.

C Jiménez1, E Marqués, C Loinaz, D R Romano, R Gómez, J C Meneu, G Hernández-Vallejo, O Alonso, M Abradelo, I Garcia, E Moreno.   

Abstract

BACKGROUND: The purpose of this study was to analyze the incidence, clinical characteristics, treatment, and outcome of upper aerodigestive (UAD) and lung de novo tumors after ortothopic liver transplantation (OLT). PATIENTS AND METHODS: Between April 1986 and June 2002, we performed 851 OLT in 753 patients. We excluded pediatric, partial, and hepatorenal transplants and recipients who died within 2 months after OLT. Thus, we analyzed the incidence and outcome of these tumors in 605 patients after OLT.
RESULTS: We found 21 (3.5%) tumors in 20 (3.3%) recipients: 14 were UAD tumors (three in floor of the mouth, two in tonsil, one in tongue, one in pharynx, three in larynx, and four in esophagus) and seven were lung tumors. Nineteen patients were men and one was a woman, with a mean age at transplantation of 47.7+/-8.6 years. Mean time from OLT to tumor diagnosis was 61.7+/-35.1 years. As risk factors, 70% were heavy smokers, 75% were heavy drinkers, and 70% developed acute rejection. The incidence of these tumors was significantly higher in transplanted patients for alcoholic cirrhosis compared to the nonalcoholic cirrhosis (8.1% vs 0.8%; P<.0001). After surgical excision in 65% of patients, 1-, 2-, and 3-year patient survival were 47.6%, 37.0%, and 19.7%, respectively.
CONCLUSION: There is a significantly higher incidence of these tumors in male heavy drinkers and/or smokers who underwent OLT for alcoholic cirrhosis; in spite of aggressive surgical treatment, the prognosis is poor.

Entities:  

Mesh:

Year:  2003        PMID: 12962840     DOI: 10.1016/s0041-1345(03)00641-9

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  8 in total

1.  Alcohol and tobacco misuse: Reducing aerodigestive cancer risk.

Authors:  Gavin Wright; Marsha Y Morgan
Journal:  World J Hepatol       Date:  2013-08-27

2.  Esophageal squamous cell carcinoma after liver transplantation.

Authors:  Alvaro Díaz de Liaño; Cristina Artieda; Concepción Yárnoz; Carlos Garde; Laura Flores; Héctor Ortiz
Journal:  Clin Transl Oncol       Date:  2005-12       Impact factor: 3.405

3.  De novo malignancy post-liver transplantation: a single center, population controlled study.

Authors:  Hemant Chatrath; Kenneth Berman; Raj Vuppalanchi; James Slaven; Paul Kwo; A Joseph Tector; Naga Chalasani; Marwan Ghabril
Journal:  Clin Transplant       Date:  2013-06-30       Impact factor: 2.863

Review 4.  Long-term survival after liver transplantation for alcoholic liver disease.

Authors:  Paula Iruzubieta; Javier Crespo; Emilio Fábrega
Journal:  World J Gastroenterol       Date:  2013-12-28       Impact factor: 5.742

Review 5.  Incidence, risk factors and outcome of de novo tumors in liver transplant recipients focusing on alcoholic cirrhosis.

Authors:  Carlos Jiménez-Romero; Iago Justo-Alonso; Félix Cambra-Molero; Jorge Calvo-Pulido; Álvaro García-Sesma; Manuel Abradelo-Usera; Oscar Caso-Maestro; Alejandro Manrique-Municio
Journal:  World J Hepatol       Date:  2015-05-08

6.  De Novo Malignancy After Living Donor Liver Transplantation: A Large Volume Experience.

Authors:  Anisha Tiwari; Sanjiv Saigal; Narendra S Choudhary; Sujeet Saha; Amit Rastogi; Prashant Bhangui; Neeraj Saraf; Thiagrajan Srinivasan; Sanjay K Yadav; Dheeraj Gautam; Samiran Nundy; Arvinder S Soin
Journal:  J Clin Exp Hepatol       Date:  2020-02-13

Review 7.  Incidence, risk factors and outcomes of de novo malignancies post liver transplantation.

Authors:  Pavan Kedar Mukthinuthalapati; Raghavender Gotur; Marwan Ghabril
Journal:  World J Hepatol       Date:  2016-04-28

Review 8.  Liver transplantation in alcoholic liver disease current status and controversies.

Authors:  Ashwani K Singal; Khushdeep S Chaha; Khalid Rasheed; Bhupinderjit S Anand
Journal:  World J Gastroenterol       Date:  2013-09-28       Impact factor: 5.742

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.